Targeting the IL1β Pathway for Cancer Immunotherapy Remodels the Tumor Microenvironment and Enhances Antitumor Immune Responses

Overview of attention for article published in Cancer Immunology Research, April 2023

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (79th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 16 X users

Citations

dimensions_citation: 3 Dimensions

Readers on

mendeley: 4 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 3 publications that cite this research output.

3

The most recent citing publications are shown below. View all 3 publications that cite this research output on Dimensions.

Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial.

Article in Journal of Clinical Oncology (December 2023)

Discovery of a selective and biologically active low-molecular weight antagonist of human interleukin-1β

Article in Nature Communications (September 2023)

Reanalysis of single-cell data reveals macrophage subsets associated with the immunotherapy response and prognosis of patients with endometrial cancer

Article in Experimental Cell Research (August 2023)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.